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CHEMOPROPHYLAXIS TO CONTROL LEPROSY AND THE PERSPECTIVE OF ITS IMPLEMENTATION 
IN BRAZIL: A PRIMER FOR NON-EPIDEMIOLOGISTS
Sergio Souza da CUNHA(1), Ana Luiza BIERRENBACH(2) & Vitor Hugo Lima BARRETO(1)
SUMMARY
The occurrence of leprosy has decreased in the world but the perspective of its elimination has been questioned. A proposed control 
measure is the use of post-exposure chemoprophylaxis (PEP) among contacts, but there are still questions about its operational aspects. 
In this text we discuss the evidence available in literature, explain some concepts in epidemiology commonly used in the research 
on this topic, analyze the appropriateness of implementing PEP in the context of Brazil, and answer a set of key questions. We argue 
some points: (1) the number of contacts that need to receive PEP in order to prevent one additional case of disease is not easy to be 
generalized from the studies; (2) areas covered by the family health program are the priority settings where PEP could be implemented; 
(3) there is no need for a second dose; (4) risk for drug resistance seems to be very small; (5) the usefulness of a serological test to 
identify a higher risk group of individuals among contacts is questionable. Given that, we recommend that, if it is decided to start 
PEP in Brazil, it should start on a small scale and, as new evidence can be generated in terms of feasibility, sustainability and impact, 
it could move up a scale, or not, for a wider intervention. 
KEYWORDS: Contact tracing; Leprosy; Prevention and control; Chemoprophylaxis.
INTRODUCTION
The occurrence of leprosy has decreased in the world, but more 
than 200,000 cases are still registered every year52 and the perspective 
of its elimination is being questioned18,19. Most of the control strategies 
rely on earlier case detection, treatment with multidrug therapy (MDT) 
and contact tracing. In Brazil, 32,945 new cases were reported in 20124 
and the Brazilian Ministry of Health officially recommended physical 
examination of all household contacts to guarantee early detection of 
new cases, and BCG vaccination. 
Another proposed control measure is the use of post-exposure 
chemoprophylaxis (PEP) among contacts of leprosy cases. PEP has been 
studied in randomized controlled trials (RCT) and observational studies 
since 1960s; the results have been summarized in two systematic literature 
reviews (SLR)36,41 and debated in the literature32,33,42,51. However, as far as 
we know, neither the World Health Organization nor the leprosy national 
programs have included PEP in their list of official recommendations. 
Given that protection has already been demonstrated, the main pending 
questions pertain to the operational aspects of implementing the PEP 
strategy43 and its real value in the control of leprosy.
In this text, we discuss the appropriateness of implementing PEP in 
Brazil by providing answers to some frequently asked questions by health 
professionals, aiming to reach a wide audience and a comprehensive 
bibliography on the topic.
What do the epidemiologic studies tell us about PEP protection 
against leprosy?
First, we need to clarify some concepts. In a RCT, the risk of leprosy 
in contacts who receive PEP is compared to contacts who do not receive 
the intervention (control). In a typical RCT, the intervention is done 
under ideal conditions and the effect is called therefore “efficacy”; if 
the study is carried out under routine conditions, the effect is called 
“effectiveness”. When an RCT reports that PEP had 50% protection, 
this means that the risk of developing the disease in contacts that 
received PEP was 50% lower than in contacts who did not receive 
PEP. But what would be the reduction in the entire population? If 50% 
of cases in the entire population came from individuals known to be 
contacts of leprosy cases, and given that PEP administered to contacts 
provides a reduction of 50% of cases among contacts, the reduction in 
the entire population would be 0.5 x 0.5 = 0.25 or 25%, considering 
that all contacts received PEP. This is called “population impact” of 
the chemoprophylaxis program. The population impact measures the 
reduction of leprosy risk in the entire population when PEP is done 
in contacts. These measures correspond to the terminology used in 
vaccine studies17. 
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It is worth saying that the RCTs on PEP were not conducted 
reproducing routine conditions of the programs where the studies were 
conducted and this has implications for the generalization of the results. 
It is not clear, for example, what would be the reduction of the risk of 
leprosy in the entire population if PEP were used in contacts in Brazil, 
due to what would be the proportion of contacts that would receive 
PEP and the high coverage rate of BCG, given that BCG also confers 
protection against leprosy23.
What was the PEP protection measured in the RCTs? 
In the six RCTs that have been published so far, PEP was done with 
several doses of acedapsone (three studies), dapsone (two studies), and 
one single dose of rifampicin (one study). The protection in contacts 
varied from 35 to 57% (all of them had statistically significant results)36,41. 
It seems that there was another unpublished study in Thailand that found 
a protection of 50%, which was not statistically significant43, but it is not 
possible to have an appraisal of this evidence.
Two additional observations are particularly important from the 
last trial, the one that used a single dose of rifampicin in Bangladesh. 
Firstly, the observed protection was higher (80%, 95% C.I.: 50-
92%) among those contacts who had been vaccinated with BCG in 
comparison to those not vaccinated (58%, 95% C.I.: 30-74%)40. This 
finding can be important because in many countries, including Brazil, 
BCG coverage rates are high and thus the protection conferred by 
PEP could eventually reach higher levels than those reported in trials. 
Secondly, the observed protection was higher among contacts who were 
not closely related to the index cases in comparison to those who were 
closely related24. This is potentially important as it could suggest that 
the implementation of PEP should also include other contacts aside from 
household members.
However, these findings should be interpreted with caution, as 
they correspond to “subgroup analyzes”: the estimation of the effect 
of an intervention separately for two or more groups of the study 
population. For example, in the comparison of the PEP effect separately 
for those with BCG and for those without BCG shown above, there 
is an overlap in the confidence intervals and therefore it cannot be 
ruled out that this difference was not obtained by chance5,21. A study 
is currently being carried out for further clarification of these different 
protection effects38.
Can PEP implemented only among contacts reduce the risk of 
disease in the entire population?
PEP is mainly recommended to a fraction of the population: those 
who are in contact with leprosy cases, and this fraction cannot be modified 
by an intervention. This means that the population impact will depend 
on two factors. Firstly, the number of cases that are directly derived from 
known/identifiable contacts. Secondly, on whether it is possible that PEP 
given to contacts can also reduce the risk among other individuals who 
do not receive PEP (this is called indirect effect) by removing the sources 
of infection and therefore reducing disease transmission. Unfortunately, 
there is no evidence so far that PEP for leprosy produces the indirect 
effect14. This means that any reduction in the entire population is due to 
reduction of cases among contacts. 
Should chemoprophylaxis also be given to the general population 
rather than only to contacts? 
The fact that there is no indirect effect could suggest that 
chemoprophylaxis should be done also in the entire population. In 
one RCT, all individuals in an endemic area were considered contacts 
and chemoprophylaxis was administered to all individuals below 
the age of 2549. One controlled but not randomized trial1 and some 
before-after observational studies8,11 have been also carried out in 
the general population with observed protection of > 75%. However, 
these observational studies are more susceptible to bias and the use of 
chemoprophylaxis in the general population poses many challenges. 
Firstly, the number of individuals receiving the drug would be high. 
Secondly, it would probably be necessary to repeat the chemoprophylaxis 
for as long as new leprosy cases occur. Operationally, this seems to 
be very difficult and probably not desirable. What could perhaps be 
reasonable is to use chemoprophylaxis in a particular small community 
with a high incidence of leprosy. But again, it is hard to define how small 
this community should be, and what would be the cut-off incidence that 
should trigger the intervention. It is likely that these questions should 
be discussed in each context.
Another issue is that the proportion of cases that comes from contacts 
seems to vary as a function of the overall occurrence of the disease: it 
seems to be higher where the occurrence of leprosy is low and smaller 
where the occurrence is high37. This implies that the population impact 
possibly varies in different settings, and thus it is not easily generalizable. 
But given that the occurrence of leprosy has decreased in Brazil, it is 
possible that the introduction of PEP will produce a higher reduction 
of cases in the entire population as a high proportion of cases acquires 
infection from contacts. 
For how long does the protection conferred by PEP among 
contacts last?
Among contacts who receive PEP, there are those who have already 
been infected by the leprosy bacilli the moment they receive PEP and 
those who have not been infected. Let us call them groups 1 and 2, 
respectively. PEP acts exclusively among group 1 contacts, but has no 
effect on group 2, even if they have the possibility of becoming infected 
afterwards. When a study compares contacts that do and do not receive 
PEP, the initial reduction among those who receive is due to the protection 
conferred to group 1. But, given time and continual exposure, new cases 
of infections will happen and disease will continue to rise, particularly 
from those in group 2. 
Therefore, it is expected that the difference in the risk of leprosy 
between those who have and have not received PEP will tend to decrease 
over the course of time35 as it was observed in the last RCT that used 
one single dose of rifampicin24, where a reduction of protection was 
observed after 2-3 years. This is not a decrease in protection, in a strict 
sense, as those in group 1 who have received PEP still have a reduced 
risk of leprosy as compared to group 1 contacts that have not received it.
However, it is important to emphasize that the risk of developing 
the disease once one has been infected tends to decrease in all contacts 
over time, having received PEP or not. This happens for two reasons. 
Firstly, most cases among contacts are paucibacillary (PB), have shorter 
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incubation period and thus infection occur sooner after exposure to the 
source. Secondly, transmission from the index cases to their contacts 
decreases gradually12,47 after they initiate MDT.
Does PEP induce drug resistance?
The use of rifampicin in contacts raises the fear of increasing drug 
resistance, as PEP would use a single dose of rifampicin for dozens of 
thousands of individuals. However, despite evidence of drug resistance to 
leprosy bacilli, it is currently rare7,50 and mostly confined to relapsed MB 
patients. Whether or not the widespread use of single antibiotics given 
on a single dose would increase the frequency of drug resistance is not 
currently known. It is possible to speculate that this is unlikely to happen, 
as it would only be a single dose given to asymptomatic individuals with 
possibly few viable bacilli instead of multiple doses given on a regular 
basis for months. But, in any case, this possibility strengthens the need 
for an effective drug resistance monitoring. 
Should a second dose of PEP be given? 
Some could argue that if protection wanes over time, a second dose 
should be repeated after two to three years in order to further decrease 
the risk of disease. However, it seems that most cases of leprosy among 
contacts are detected in the first two to three years after the detection 
of the index cases. This information is available in some prospective 
studies of contacts (Table 1). It was also described in a cohort study 
performed in Brazil20,39. Because of this fact, as compared to the first 
dose of PEP, each subsequent dose will prevent less and less cases from 
occurring. Therefore, it is possible that repeated PEP doses over time 
are unnecessary. 
The case for a broader contact definition
The greater the proportion of cases arising from contacts, the greater 
the impact of PEP in the entire population. In a study in Indonesia, 79% 
of cases were from contacts including neighbour and social contacts46. 
Therefore, one solution to increase the impact on the population would 
be to broaden the contact definition. However, this would obviously 
increase costs and logistic efforts to find such contacts, and to convince 
them of the need to receive PEP. A broader definition was used in the 
last trial24, but it is unclear whether it would be feasible to use the same 
wide definition under routine conditions.
Can BCG and rifampicin be given at the same moment to 
contacts?
In Brazil,  according to the National Leprosy Program 
recommendations, BCG vaccine should be administered to those in 
contact with leprosy cases. In order to prevent the bactericidal activity 
of rifampicin from interfering with the immunization conferred by BCG 
(a live vaccine that dies with rifampicin use), it seems reasonable that 
PEP and BCG should not be given together. In an ongoing study, BCG 
Table 1
Percentage of leprosy cases detected during follow-up in different longitudinal studies with contacts of leprosy cases
Study: Author, year of first 
publication, references Study
1 Total duration of follow-up Percentage of cases per follow-up period in 
the control group
Moet, 200814,24 RCT for chemoprophylaxis 5-6 years Total: 108 
1-2 years: 67 (62.0%) 
3-4 years: 24 (22.2%) 
5-6 years: 17 (15.7%)
Neelan, 198325 RCT for chemoprophylaxis Up to 180 weeks (∼3.4 years) Total: 42 
Up to 90 weeks: 37 (88%)
Noordeen, 1976 29,31 RCT for chemoprophylaxis Contacts of “non-lepromatous 
cases” = 3.5 years (185 weeks)
Total: 109 
Up to 119 weeks (∼ 2.2 years): 84 (77%)
Contacts of lepromatous cases = 6 
years (318 weeks)
Total: 38 
Up to 150 weeks (∼ 2.8 years): 34 (89%)
Dharmendra, 1965 9,10,28,30 RCT for chemoprophylaxis 3rd report up to 299 weeks (∼ 5.6 
years) 
(Last report up to 8 ½ years but with 
small cases of follow-up)
Total with 299 weeks: 48 
Up to 149 weeks (∼2.8 years): 39 (81%)
Stanley, 198145 RCT for BCG in contacts 8 years Total: 192 cases2  
Separately for survey and mean years for 
entry:  
1st (mean 1.9 years): 103 (54%) 
2nd (mean 3.3 years): 51 (27%)  
3rd (mean 5.7 years): 27 (14%) 
4th (mean 8.0 years): 11 (6%)
Notes: 1RCT randomised control trial; 2as in table 6 of the reference.
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and PEP are being administered two months apart38. In Brazil, BCG is 
given to contacts and thus a clear recommendation should be made on 
administration intervals under routine situations. It is not known whether 
or not this gap would have implications for the follow-up of contacts. 
Should a test be implemented to detect contacts that are exposed 
to a higher risk?
Based on the results of some studies, it has been suggested that 
programs should use a serological test to identify, among contacts, an 
even higher risk group of individuals that would be followed under a 
closer surveillance12,13. 
However, these results should be interpreted very carefully. Despite 
the fact that individuals who are positive to such tests have been shown 
to have a higher risk of getting the disease in comparison to those who 
are negative, it seems that the majority of new cases still arise from those 
who are negative, so surveillance would still be necessary for all contacts 
regardless of test results. Therefore, the real utility of implementing such 
tests in the routine of leprosy control activities is still to be demonstrated.
Let us consider an example of a study on this regard performed in 
Brazil13. In this study, 2,135 contacts had a serological test (PGL-1) and 
16% were found to be positive (n = 342). After a follow-up of several 
years, 60 new cases were detected and the authors estimated that those 
with a positive test had a chance 3.2 times more than those with a negative 
test. However, the majority of cases occurred among negative contacts: 
68% (41/60) were negative and 32% (19/60) were positive. In contrast, it 
was also observed that 90% (54/60) of the cases were from 1,570 contacts 
of index cases that were multibacillary (MB). If the justification for 
serology is to perform a close monitoring in a subgroup responsible for 
the majority of cases, it seems that obtaining the mere information of the 
clinical form of the index cases would be more useful, unless, someone 
could argue, maybe rightly, that it is easier to have a closer monitoring of 
342 rather than of 1,570 individuals. In another study in the Philippines, 
multiple serological tests were performed to identify contacts at higher 
risks12, with 559 contacts and 27 new cases diagnosed (10 MB and 17 
PB). The risk of becoming a case for those who were positive was 7.15 
higher than for those who were negative. But again, among the 27 new 
cases, only a minority (n = 7) were positive in the first test (25.9%), 
other seven seroconverted during follow-up, and 13 remained negative 
throughout follow-up. In this study, it seems that performing just one 
test to identify contacts that have a higher risk of becoming a case was 
not a good initiative, as these tests only predicted a minority of cases. 
Multiple tests would therefore need to be performed over time, increasing 
costs and logistics.
There is evidence supporting the fact that MB cases are the main 
source of infection, and so a close monitoring of their positive contacts 
could help to break the chain of transmission12. However, in the Brazilian 
study13, out of the six new MB cases that were detected, four had been 
positive for the serological test; in the study in the Philippines12, among 
10 new MB cases, only three had been positive at the first exam. Indeed, 
it seems that the test is capable of identifying a subgroup in which most 
MB cases arise, but not all of them. Whether or not this could help to 
break the chain of leprosy transmission is yet to be demonstrated. 
From an individual perspective, it could be desirable to determine 
through a simple serological test whether or not one has a higher risk of 
becoming a case. However, from the perspective of a control program, 
it should be considered whether or not this initiative actually contributes 
to decreasing the incidence of leprosy, to identifying most of those that 
would become new cases of leprosy (irrespective of them being a PB or 
an MB cases), or most new MB cases. The introduction of a test capable 
of identifying only a minority of the total cases and not even all MB cases 
will possibly not make much difference in practice, because contacts 
tested positive, negative and untested should still be ultimately monitored. 
New field-friendly assays testing M. leprae-specific T cell responses 
seem to be more promising3,16. However, longitudinal studies are still 
needed to assess the accuracy in predicting who, among those who are 
healthy household contacts, has a higher risk of developing clinical 
leprosy.
Whatever the diagnostic test used, the whole strategy combining 
testing plus close monitoring should also be evaluated on the basis of 
its feasibility and costs, the compliance of positive contacts to the closer 
monitoring procedures, some quantification of how much earlier cases 
arising from positive contacts monitored closely would be detected in 
comparison to those followed under the routine surveillance; as well as 
the proportion of the total and MB cases arising from positive contacts.
Number needed to treat (NNT)
The NNT is the number of people that need to be treated (or need 
to use PEP) in order to prevent an additional case of disease2. If NNT is 
high, the intervention will possibly not be feasible and/or it will be too 
expensive. When the risk of leprosy is low in a population, more contacts 
have to receive chemoprophylaxis to prevent a new case, and vice versa. 
NNT has been estimated in several PEP studies. However, it is 
important to emphasize that the interpretation of NNT should be done 
very carefully22,44 as it depends highly on the absolute baseline risk 
and for how long NNT is measured. For example, if in a hypothetical 
scenario the risk of leprosy among contacts is 4% in one year from the 
detection of the index case, then this would mean that among 1,000 
contacts, 40 new cases would be detected during this period. However, 
if all 1,000 contacts receive the chemoprophylaxis and its effectiveness 
is 50%, 20 cases will be prevented. The NNT would be 50 (1,000/20). 
In another scenario in which the risk is lower (0.4%) there would be 
only four cases in one year and the NNT would be 500 (1,000/2). But 
if NNT is measured for two years and eight cases are detected instead 
of four, and four cases prevented instead of two, the NNT now would 
be 250 (1,000/4). This implies that NNT is difficult to be generalized. 
Table 2 shows the estimates in different studies and these estimates 
varied from 14 to 265.
How can these estimates be compared with incidence and NNT in 
contacts in Brazil? In a cohort study done in Rio de Janeiro20, an incidence 
rate of 16.94/1,000 person-years was reported. As the mean duration 
of follow-up was four years, the risk of leprosy among contacts can be 
estimated as 1-exponential(- incidence rate x time)6 which would give us the value of 
6.6%. If PEP protection is assumed to be 50%, the risk of leprosy among 
contacts submitted to the intervention will be half 6.6%, i.e. 3.3%, and 
thus the NNT will be 1/(0.066-0.033), which is similar to administering 
PEP to 30 contacts to prevent one new additional case over four years. 
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Whether or not the risk of leprosy among contacts estimated in this 
study can be generalized to the whole Brazilian scenario is doubtful. 
For example, 900 cases were reported in 2012 in Sao Luis do Maranhao 
(population of 1,331,180), which reflects a new case detection rate close 
to 7/10,000 in the general population4. If it were assumed that the risk in 
contacts is ten times higher than in the general population (a rather high 
estimate in comparison to the literature), the risk in contacts would be 
0.007 and NNT (assuming that protection is 50%) would be 1/(0.007-
0.0035) or ∼ 285. Most endemic areas have an incidence of leprosy lower 
than that of Sao Luis do Maranhao. Therefore, it seems that is not easy 
to generalize results from the studies in different settings.
The role of the PSF
Most municipalities in Brazil are now covered by the Family Health 
Program (Programa de Saúde da Familia, PSF)34. Each PSF unit has 
a team of community health workers (Agente Comunitário de Saúde, 
ACS), and each ACS has a list of all families and individuals in the 
catchment area. Some potential advantages of integrating the leprosy 
control activities in the routine of PSF and ACS are presented below. 
1. It can facilitate (1) the examination of neighbours without disclosing 
the diagnosis of the index case, and (2) the adoption of a broader 
definition of contacts;
2. It would be easier to monitor PEP performance, i.e. the degree to 
which an intervention operates according to specific standards or 
guidelines, or achieves results in accordance with stated goals or 
plans15, by establishing indicators such as the number of contacts 
needed to be examined to find one new case among each of the 
catchment areas, or among households or neighbours of index cases;
3. It would be easier to measure the population impact in the mid -or 
long- term, as well as monitoring the adverse events due to BCG 
vaccination and use of chemoprophylaxis;
4. It would be easier to collect data about costs of contact tracing and 
to estimate the cost to detect one case based on routine, the cost of a 
more active surveillance and of contact tracing among neighbours, 
and its sustainability; 
5. It would be easier to understand the health care seeking behavior 
of patients and to implement approaches to manage stigma and to 
diminish the observed barriers for contact tracing and to seek health 
services to examination;
6. It would facilitate the implementation of health education programs 
promoting self-examination; 
7. It would facilitate surveillance of cases and contacts, and the routine 
data can be used to create a cohort of individuals in whom the 
reduction of disease in contacts and population can be estimated. 
However, it is still necessary to acquire a better knowledge on whether 
the implementation of such intense activities would have negative effects 
on the other PSF routine activities .
Concluding remarks
What is the next step? Do we need more studies to implement PEP? 
In our opinion, there is enough evidence supporting the effectiveness of 
PEP, and the PSF areas seem to be the priority settings where PEP could 
be implemented. However, other aspects should be considered to make 
a decision. Firstly, aspects related to sustainability of this intervention 
should be considered such as cost/effectiveness comparing the different 
alternatives of intervention, performance monitoring and intervention 
impact48. Secondly, what would be the additional reduction of leprosy 
occurrence given that (1) the incidence of leprosy is steadily decreasing 
in Brazil, (2) PEP does not change the social determinants of the disease, 
and (3) there is evidence that the presence of other public interventions 
can have an impact in the reduction of leprosy27. 
Table 2
Estimate of the number of contacts to receive chemoprophylaxis needed to prevent one case of leprosy (NNT) among contacts
Study: Author, year of first 
publication, references
Estimate of baseline risk (%) in contacts 
controls
Estimate of risk in 
intervention group Years of follow-up Estimate of NNT
2
Moet, 200824 1-2 years: 67 cases in 10,006 = 0.66% 1-2 years 
29 in 9951 = 0.29%
2 2653
Neelan, 198325 42 cases in 351 = 12.0% 22/358 = 6.1% 3 ½ 17
Noordeen, 197629 “non-lepromatous” 
109/1000 = 10.9%  
 
“lepromatous” 
38/319 = 11.9%
 
72/1000 = 7.2% 
 
 
53/636 = 8.3%
 
3½ 
 
5
 
27 
 
 
27
Dharmendra, 196710 2nd survey1 
 41/316 = 13%
 
19/316 = 6%
 
3 ½
 
14
Neelan, 198626  30/280 = 10.7 % 13/280 = 4.6% ∼ 4.2 16
Wardekar, 196749 119/11697 = 1.01% 43/11676 = 0.37% 2 154
Note 1: There is a report with results for the 3rd survey with 5 ½ years28, but because the amount of missing data, it was chosen to use data from the 2nd survey; 2 the NNT 
was calculated as 1 ÷ (incidence proportion in control - incidence proportion in intervention); 3 as in the reference. 
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As PEP benefits and feasibility are not fully established, we 
recommend that, if a decision is made to start PEP, this should start on 
a small scale and, as new evidence can be generated, it could provide 
the basis to move up a scale, or not, to a wider intervention. Some 
priority municipalities could be chosen to be the first wave of PEP 
implementation. The National Leprosy Program, alongside the academic 
community, could also use the opportunity of PEP implementation to 
plan for some pragmatic epidemiological studies, mimicking routine 
conditions, that would aim to respond some of the various remaining 
questions about PEP, such as whether or not to use a broader definition 
of contacts, the need to use a test to identify contacts with a higher risk, 
and PEP effects on drug resistance. 
RESUMO
Quimioprofilaxia para prevenção de hanseníase e sua implantação 
no Brasil: uma explicação introdutória para não epidemiologistas
A ocorrência de hanseníase tem diminuído no mundo apesar de que a 
perspectiva de sua eliminação tem sido questionada. Uma proposta para 
o controle da endemia é a quimioprofilaxia pós-exposição entre contatos 
(post-exposure chemoprophylaxis, PEP), embora ainda existam dúvidas 
quanto aos seus aspectos operacionais e generalização de resultados. 
Nesse texto nós discutimos as evidências disponíveis na literatura, 
explicamos alguns conceitos epidemiológicos comumente encontrados 
em pesquisa sobre PEP e a implantação da PEP no contexto brasileiro. 
Nós argumentamos que: (1) a estimativa em diferentes estudos do numero 
de contatos necessário para receber PEP para prevenir um novo caso de 
hanseníase (number needed to treat, NNT) não é facilmente generalizável; 
(2) áreas cobertas pelo programa de saúde da família são as áreas 
prioritárias onde PEP poderia ser implantado; (3) não existe necessidade 
de segunda dose da quimioprofilaxia; (4) o risco de resistência à droga 
usada na PEP parece ser muito pequeno; (5) questionamos a necessidade 
de teste sorológico para identificar indivíduos entre os contatos que 
tenham maior risco de doença. Nós opinamos que, se houver uma decisão 
para se iniciar PEP no Brasil, essa intervenção deveria ser iniciada em 
pequena escala e, à proporção que novas evidências são geradas sobre a 
factibilidade, sustentabilidade e impacto da intervenção, a intervenção 
com PEP poderia ou não ser usada em larga escala. 
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